MA38239A1 - Nouveaux dérivés de pyridine - Google Patents

Nouveaux dérivés de pyridine

Info

Publication number
MA38239A1
MA38239A1 MA38239A MA38239A MA38239A1 MA 38239 A1 MA38239 A1 MA 38239A1 MA 38239 A MA38239 A MA 38239A MA 38239 A MA38239 A MA 38239A MA 38239 A1 MA38239 A1 MA 38239A1
Authority
MA
Morocco
Prior art keywords
pyridine derivatives
new pyridine
new
compound
formula
Prior art date
Application number
MA38239A
Other languages
English (en)
French (fr)
Inventor
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Beat Frei
Luca Gobbi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38239A1 publication Critical patent/MA38239A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA38239A 2012-12-07 2013-12-02 Nouveaux dérivés de pyridine MA38239A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12196022 2012-12-07
PCT/EP2013/075225 WO2014086705A1 (en) 2012-12-07 2013-12-02 Novel pyridine derivatives

Publications (1)

Publication Number Publication Date
MA38239A1 true MA38239A1 (fr) 2017-03-31

Family

ID=47290804

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38239A MA38239A1 (fr) 2012-12-07 2013-12-02 Nouveaux dérivés de pyridine

Country Status (33)

Country Link
US (1) US9522886B2 (enExample)
EP (2) EP3357918A1 (enExample)
JP (1) JP6426618B2 (enExample)
KR (1) KR20150092282A (enExample)
CN (2) CN107674061A (enExample)
AR (1) AR093843A1 (enExample)
AU (2) AU2013354278B2 (enExample)
BR (1) BR112015012919A2 (enExample)
CA (1) CA2890100A1 (enExample)
CL (1) CL2015001536A1 (enExample)
CO (1) CO7350620A2 (enExample)
CR (1) CR20150250A (enExample)
DK (1) DK2928881T3 (enExample)
EA (1) EA026669B1 (enExample)
ES (1) ES2668690T3 (enExample)
HR (1) HRP20180672T1 (enExample)
HU (1) HUE036911T2 (enExample)
IL (1) IL239075B (enExample)
LT (1) LT2928881T (enExample)
MA (1) MA38239A1 (enExample)
MX (1) MX2015007155A (enExample)
NO (1) NO2928881T3 (enExample)
PE (1) PE20151025A1 (enExample)
PH (1) PH12015501083A1 (enExample)
PL (1) PL2928881T3 (enExample)
PT (1) PT2928881T (enExample)
RS (1) RS57143B1 (enExample)
SG (2) SG11201504416XA (enExample)
SI (1) SI2928881T1 (enExample)
TW (1) TWI600645B (enExample)
UA (1) UA114656C2 (enExample)
WO (1) WO2014086705A1 (enExample)
ZA (1) ZA201503969B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151539A1 (es) 2013-03-07 2015-10-28 Hoffmann La Roche Nuevos derivados de pirazol
ES2661737T3 (es) 2013-03-26 2018-04-03 F. Hoffmann-La Roche Ag Derivados de piridina novedosos
MY182237A (en) 2013-05-02 2021-01-18 Hoffmann La Roche Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
BR112015027396B1 (pt) 2013-05-02 2023-04-11 F. Hoffmann-La Roche Ag Derivados de purina como agonistas do receptor de cb2
KR20220140651A (ko) 2013-09-06 2022-10-18 에프. 호프만-라 로슈 아게 신규의 트라이아졸로[4,5-d]피리미딘 유도체
JP6353072B2 (ja) * 2014-04-04 2018-07-04 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft カンナビノイド受容体アゴニストとしての5,6−二置換ピリジン−2−カルボキサミド
US10214508B2 (en) 2014-06-13 2019-02-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
SI3386951T1 (sl) * 2015-12-09 2020-07-31 F. Hoffmann-La Roche Ag Fenilni derivati kot agonisti kanabinoidnega receptorja 2
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
EP3642200B1 (en) 2017-06-20 2023-05-03 F. Hoffmann-La Roche AG Pyridine derivatives
EP3781551A1 (en) * 2018-04-18 2021-02-24 Basf Se D-glucaro-6,3-lactone monoester and a process for the preparation thereof
IL279725B2 (en) 2018-06-27 2024-04-01 Eth Zuerich Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
EP3814328A1 (en) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
JP7454512B2 (ja) 2018-06-27 2024-03-22 エフ. ホフマン-ラ ロシュ アーゲー 優先的カンナビノイド2アゴニストとしてのピリジン及びピラジン誘導体
JP7456948B2 (ja) 2018-06-27 2024-03-27 エフ. ホフマン-ラ ロシュ アーゲー 放射性標識カンナビノイド受容体2リガンド
EP4038055A1 (en) * 2019-09-30 2022-08-10 F. Hoffmann-La Roche AG Substituted 3,4-dihydroquinazoline for the treatment and prophylaxis of hepatitis b virus infection
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
JP2024518145A (ja) * 2021-04-19 2024-04-25 ケモセントリックス,インコーポレイティド Cxcr7阻害剤としてのアゼチジニル-アセトアミド
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
CN119584994A (zh) 2022-05-02 2025-03-07 普雷西里克斯公司 预靶向

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2076499B1 (en) * 2006-10-04 2010-05-12 F.Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
AR085013A1 (es) * 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor

Also Published As

Publication number Publication date
EA026669B1 (ru) 2017-05-31
CR20150250A (es) 2015-06-11
HK1208031A1 (en) 2016-02-19
PH12015501083B1 (en) 2015-08-03
HRP20180672T1 (hr) 2018-06-01
SG11201504416XA (en) 2015-07-30
US9522886B2 (en) 2016-12-20
PE20151025A1 (es) 2015-07-15
PT2928881T (pt) 2018-05-07
AU2013354278A1 (en) 2015-05-14
US20150307452A1 (en) 2015-10-29
EP2928881B1 (en) 2018-03-14
CN107674061A (zh) 2018-02-09
LT2928881T (lt) 2018-06-11
BR112015012919A2 (pt) 2017-07-11
SI2928881T1 (en) 2018-07-31
EA201591064A1 (ru) 2015-09-30
NO2928881T3 (enExample) 2018-08-11
CO7350620A2 (es) 2015-08-10
RS57143B1 (sr) 2018-07-31
SG10201800170YA (en) 2018-02-27
AU2013354278B2 (en) 2017-10-12
TW201427951A (zh) 2014-07-16
ZA201503969B (en) 2016-04-28
JP2016501240A (ja) 2016-01-18
CL2015001536A1 (es) 2015-10-23
CN104837831B (zh) 2017-10-31
IL239075B (en) 2018-11-29
CA2890100A1 (en) 2014-06-12
UA114656C2 (uk) 2017-07-10
EP2928881A1 (en) 2015-10-14
AR093843A1 (es) 2015-06-24
ES2668690T3 (es) 2018-05-21
KR20150092282A (ko) 2015-08-12
JP6426618B2 (ja) 2018-11-21
PH12015501083A1 (en) 2015-08-03
CN104837831A (zh) 2015-08-12
MX2015007155A (es) 2015-10-14
TWI600645B (zh) 2017-10-01
IL239075A0 (en) 2015-07-30
PL2928881T3 (pl) 2018-07-31
WO2014086705A1 (en) 2014-06-12
AU2017279648A1 (en) 2018-01-18
HUE036911T2 (hu) 2018-08-28
EP3357918A1 (en) 2018-08-08
DK2928881T3 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
MA38239A1 (fr) Nouveaux dérivés de pyridine
MA40308A1 (fr) Pyridine-2- amides utiles comme agonistes de cb2
MA38404A1 (fr) Nouveaux dérivés de pyridine
MA38238B1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
EA201591527A1 (ru) Новые производные пиридина
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
MA38460A1 (fr) Dérivés de la purine en tant qu'agonistes du récepteur cb2
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
MA38583A1 (fr) Dérivés de dolastatine 10 et d'auristatines
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
MA38555A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MA43400B1 (fr) Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
JO3264B1 (ar) مركبات ازيتيدينيل أوكسي فينيل بيروليدين
MA33985B1 (fr) Dérivés fluorés de 3-hydroxypyridin-4-ones
MA37920A1 (fr) Amino-quinoléines servant d'inhibiteurs de kinase